Effect of Formulation Parameters on Pharmacokinetics, Pharmacodynamics, and Safety of Diclofenac Nanomedicine

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2019 Mar 24

PMID 30903395

Citations 5

Authors

Dhanya Narayanan

Gopikrishna J Pillai

Shantikumar V Nair

Deepthy Menon

Affiliations

Soon will be listed here.

Abstract

This study reports the development of a nanoformulation of diclofenac sodium, a potent non-steroidal anti-inflammatory drug, at its clinical dose, utilizing a FDA approved polymer, hydroxyethyl starch. The study specifically focused on the control of pharmacokinetics, pharmacodynamics, and biodistribution by particle surface functionalization and alteration of excipient levels in the final formulation. Stable diclofenac sodium-loaded hydroxyethyl starch nanoparticles (nanodiclo) of size 170 ± 5 nm and entrapment efficiency 72 ± 3% were prepared. Free diclofenac, nanodiclo, nanodiclo surface functionalized by PEGylation, nanodiclo with excipients removed, and finally PEGylated nanodiclo with excipients removed were all tested comparatively at two different doses. The results showed substantial impact of both excipients and PEGylation on the pharmacokinetics and pharmacodynamics in vivo. Further, the results proved that excipient removed PEGylated nanodiclo at lower dose achieved clinical therapeutic levels in blood for up to 120 h, with minimal accumulation in critical organs, and much better efficacy than other controls.

Citing Articles

Coprecipitation of Class II NSAIDs with Polymers for Oral Delivery.

De Marco I Polymers (Basel). 2023; 15(4).

PMID: 36850237 PMC: 9959069. DOI: 10.3390/polym15040954.

Advanced Skin Antisepsis: Application of UVA-Cleavable Hydroxyethyl Starch Nanocapsules for Improved Eradication of Hair Follicle-Associated Microorganisms.

Busch L, Hanuschik A, Avlasevich Y, Darm K, Hochheiser E, Kohler C Pharmaceutics. 2023; 15(2).

PMID: 36839931 PMC: 9966858. DOI: 10.3390/pharmaceutics15020609.

Hydroxyethyl starch based smart nanomedicine.

Wang H, Hu H, Yang H, Li Z RSC Adv. 2022; 11(6):3226-3240.

PMID: 35424303 PMC: 8694170. DOI: 10.1039/d0ra09663f.

Development and Optimization of Nanolipid-Based Formulation of Diclofenac Sodium: In Vitro Characterization and Preclinical Evaluation.

Zafar A, Alruwaili N, Imam S, Yasir M, Alsaidan O, Alquraini A Pharmaceutics. 2022; 14(3).

PMID: 35335883 PMC: 8949207. DOI: 10.3390/pharmaceutics14030507.

Quantitation of Diclofenac, Tolbutamide, and Warfarin as Typical CYP2C9 Substrates in Rat Plasma by UPLC-MS/MS and Its Application to Evaluate Linderane-Mediated Herb-Drug Interactions.

Zhang T, Peng T, Rao J, Wang K, Qiu F J Anal Methods Chem. 2022; 2022:1900037.

PMID: 35309717 PMC: 8930270. DOI: 10.1155/2022/1900037.

References

He C, Hu Y, Yin L, Tang C, Yin C . Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010; 31(13):3657-66. DOI: 10.1016/j.biomaterials.2010.01.065. View

Bort R, Ponsoda X, Jover R, Gomez-Lechon M, Castell J . Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther. 1998; 288(1):65-72. View

Alexis F, Pridgen E, Molnar L, Farokhzad O . Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5(4):505-15. PMC: 2663893. DOI: 10.1021/mp800051m. View

Garg V, Jain G, Nirmal J, Kohli K . Topical tacrolimus nanoemulsion, a promising therapeutic approach for uveitis. Med Hypotheses. 2013; 81(5):901-4. DOI: 10.1016/j.mehy.2013.08.007. View

Merkel T, Jones S, Herlihy K, Kersey F, Shields A, Napier M . Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci U S A. 2011; 108(2):586-91. PMC: 3021010. DOI: 10.1073/pnas.1010013108. View

Liu D, Ge Y, Tang Y, Yuan Y, Zhang Q, Li R . Solid lipid nanoparticles for transdermal delivery of diclofenac sodium: preparation, characterization and in vitro studies. J Microencapsul. 2010; 27(8):726-34. DOI: 10.3109/02652048.2010.513456. View

Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O . Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2007; 83(5):761-9. DOI: 10.1038/sj.clpt.6100400. View

Park J, Fong P, Lu J, Russell K, Booth C, Saltzman W . PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine. 2009; 5(4):410-8. PMC: 2789916. DOI: 10.1016/j.nano.2009.02.002. View

Tolman K . Hepatotoxicity of non-narcotic analgesics. Am J Med. 1998; 105(1B):13S-19S. DOI: 10.1016/s0002-9343(98)00070-9. View

10.

Hemmila M, Mattar A, Taddonio M, Arbabi S, Hamouda T, Ward P . Topical nanoemulsion therapy reduces bacterial wound infection and inflammation after burn injury. Surgery. 2010; 148(3):499-509. PMC: 2891388. DOI: 10.1016/j.surg.2010.01.001. View

11.

Pillai G, Greeshma M, Menon D . Impact of poly(lactic-co-glycolic acid) nanoparticle surface charge on protein, cellular and haematological interactions. Colloids Surf B Biointerfaces. 2015; 136:1058-66. DOI: 10.1016/j.colsurfb.2015.10.047. View

12.

Kandadi P, Afzal Syed M, Goparaboina S, Veerabrahma K . Albumin coupled lipid nanoemulsions of diclofenac for targeted delivery to inflammation. Nanomedicine. 2011; 8(7):1162-71. DOI: 10.1016/j.nano.2011.12.006. View

13.

Seth B . Comparative pharmacokinetics and bioavailability study of percutaneous absorption of diclofenac from two topical formulations containing drug as a solution gel or as an emulsion gel. Arzneimittelforschung. 1992; 42(2):120-2. View

14.

Alexis F, Rhee J, Richie J, Radovic-Moreno A, Langer R, Farokhzad O . New frontiers in nanotechnology for cancer treatment. Urol Oncol. 2008; 26(1):74-85. DOI: 10.1016/j.urolonc.2007.03.017. View

15.

Narayanan D, M G G, H L, Koyakutty M, Nair S, Menon D . Poly-(ethylene glycol) modified gelatin nanoparticles for sustained delivery of the anti-inflammatory drug Ibuprofen-Sodium: an in vitro and in vivo analysis. Nanomedicine. 2013; 9(6):818-28. DOI: 10.1016/j.nano.2013.02.001. View

16.

Carson J, Notis W, Orris E . Colonic ulceration and bleeding during diclofenac therapy. N Engl J Med. 1990; 323(2):135. DOI: 10.1056/NEJM199007123230217. View

17.

Narayanan D, Nair S, Menon D . A systematic evaluation of hydroxyethyl starch as a potential nanocarrier for parenteral drug delivery. Int J Biol Macromol. 2015; 74:575-84. DOI: 10.1016/j.ijbiomac.2014.12.012. View

18.

Warner T, Giuliano F, Vojnovic I, Bukasa A, Mitchell J, Vane J . Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999; 96(13):7563-8. PMC: 22126. DOI: 10.1073/pnas.96.13.7563. View

19.

Kean W, Buchanan W . The use of NSAIDs in rheumatic disorders 2005: a global perspective. Inflammopharmacology. 2005; 13(4):343-70. DOI: 10.1163/156856005774415565. View

20.

Kumar R, Chen M, Parmar V, Samuelson L, Kumar J, Nicolosi R . Supramolecular assemblies based on copolymers of PEG600 and functionalized aromatic diesters for drug delivery applications. J Am Chem Soc. 2004; 126(34):10640-4. DOI: 10.1021/ja039651w. View